Okay.
I'd still think the fastest path, even with a few month delay, is to get Rett approved and use the voucher to accelerate approval for Blarcamesine. Even though we may think it's the most important drug in the FDA's docket, the FDA may not feel it's as big of a priority as say, a new cancer drug that requires the same amount of manpower to review.
I'd rather have the voucher and know that Anavex will be escorted to the front of the review process line.